Clinical efficacy, safety and inhibition of joint destruction of adalimumab in the treatment of moderate to severe psoriatic arthritis: 48-week results of the ADEPT trial

被引：0
|
作者：
Mease, P
Gladman, D
Ritchlin, C
Weinberg, M
机构：
[1] Swedish Med Ctr, Seattle, WA USA
[2] Univ Toronto, Toronto, ON, Canada
[3] Univ Rochester, Sch Med & Dent, Rochester, NY USA
[4] Abbott Labs, Abbott Pk, IL 60064 USA
来源：
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY | 2006年 / 54卷 / 03期
关键词：
D O I：
暂无
中图分类号：
R75 [皮肤病学与性病学];
学科分类号：
100206 ;
摘要：
引用
下载
收藏
页码：AB214 / AB214
页数：1
相关论文
共 50 条
  • [31] Efficacy and Safety of Risankizumab for Active Psoriatic Arthritis: 100-Week Results from the Phase 3 KEEPsAKE 1 Randomized Clinical Trial
    Kristensen, Lars Erik
    Keiserman, Mauro
    Papp, Kim
    Mccasland, Leslie
    White, Douglas
    Carter, Kyle
    Lippe, Ralph
    Photowala, Huzefa
    Drogaris, Leonidas
    Soliman, Ahmed M.
    Chen, Michael
    Padilla, Byron
    Behrens, Frank
    RHEUMATOLOGY AND THERAPY, 2024, 11 (03) : 617 - 632
  • [32] Efficacy and safety of etravirine (TMC125) in treatment-experienced HIV-1-infected patients: 48-week results of a phase IIb trial
    Cohen, Calvin J.
    Berger, Daniel S.
    Blick, Gary
    Grossman, Howard A.
    Jayaweera, Dushyantha T.
    Shalit, Peter
    Thompson, Melanie
    Peeters, Monika
    de Bethune, Marie-Pierre
    Voorspoels, Ellen
    Mack, Rebecca
    Woodfall, Brian
    AIDS, 2009, 23 (03) : 423 - 426
  • [33] Switching to Biosimilar SDZ-ADL in Patients with Moderate-to-Severe Active Rheumatoid Arthritis: 48-Week Efficacy, Safety and Immunogenicity Results From the Phase III, Randomized, Double-Blind ADMYRA Study
    Wiland, Piotr
    Jeka, Slawomir
    Dokoupilova, Eva
    Brandt-Juergens, Jan
    Miranda Limon, Juan Manuel
    Cantalejo Moreira, Miguel
    Veiga Cabello, Raul
    Jauch-Lembach, Julia
    Thakur, Anjali
    Haliduola, Halimuniyazi
    Brueckmann, Ines
    Gaylis, Norman B.
    BIODRUGS, 2020, 34 (06) : 809 - 823
  • [34] Switching to Biosimilar SDZ-ADL in Patients with Moderate-to-Severe Active Rheumatoid Arthritis: 48-Week Efficacy, Safety and Immunogenicity Results From the Phase III, Randomized, Double-Blind ADMYRA Study
    Piotr Wiland
    Sławomir Jeka
    Eva Dokoupilová
    Jan Brandt-Jürgens
    Juan Manuel Miranda Limón
    Miguel Cantalejo Moreira
    Raul Veiga Cabello
    Julia Jauch-Lembach
    Anjali Thakur
    Halimuniyazi Haliduola
    Ines Brueckmann
    Norman B. Gaylis
    BioDrugs, 2020, 34 : 809 - 823
  • [35] Efficacy of ixekizumab vs. adalimumab in patients with psoriatic arthritis with moderate-to-severe psoriasis: 52-week results from a multicentre, randomized, open-label study
    Kleyn, C. E.
    Gooderham, M.
    Kristensen, L. E.
    de Vlam, K.
    Schuster, C.
    Leage, S. Liu
    McKenzie, R.
    Sapin, C.
    Li, L.
    Griffiths, C. E. M.
    BRITISH JOURNAL OF DERMATOLOGY, 2020, 183 : 70 - 71
  • [36] SWITCH BETWEEN REFERENCE ETANERCEPT (ETN) AND GP2015, AN ETANERCEPT BIOSIMILAR, DID NOT IMPACT EFFICACY AND SAFETY IN PATIENTS WITH MODERATE-TO-SEVERE RHEUMATOID ARTHRITIS: 48-WEEK RESULTS FROM THE PHASE 3 EQUIRA STUDY
    Matucci-Cerinic, M.
    Schulze-Koops, H.
    Buch, M.
    Kavanaugh, A.
    Allanore, Y.
    Kucharz, E. J.
    Babic, G.
    ANNALS OF THE RHEUMATIC DISEASES, 2018, 77 : 609 - 609
  • [37] Consistent responses to guselkumab by disease region at week 48 in the treatment of moderate-to-severe psoriasis: ECLIPSE trial results
    Langley, R. G.
    Ferris, L.
    Gebauer, K.
    Arenberger, P.
    Gooderham, M.
    Guenther, L.
    Flavin, S.
    Li, S.
    Randazzo, B.
    Armstrong, A.
    AUSTRALASIAN JOURNAL OF DERMATOLOGY, 2021, 62 : 58 - 58
  • [38] No overall damage progression despite persistent inflammation in adalimumab-treated psoriatic arthritis patients: results from an investigator-initiated 48-week comparative magnetic resonance imaging, computed tomography and radiography trial
    Poggenborg, Rene Panduro
    Wiell, Charlotte
    Boyesen, Pernille
    Boonen, Annelies
    Bird, Paul
    Pedersen, Susanne Juhl
    Sorensen, Inge Juul
    Madsen, Ole Rintek
    Slot, Ole
    Moller, Jakob M.
    Hasselquist, Maria
    Kubassova, Olga
    Ostergaard, Mikkel
    RHEUMATOLOGY, 2014, 53 (04) : 746 - 756
  • [39] EFFICACY OF IXEKIZUMAB VERSUS ADALIMUMAB IN PSORIATIC ARTHRITIS (PSA) PATIENTS WITH AND WITHOUT MODERATE-TO-SEVERE PSORIASIS: 52-WEEK RESULTS FROM A MULTICENTRE, RANDOMISED OPEN-LABEL STUDY
    Kristensen, Lars-Erik
    Okada, Masato
    Tillett, William
    Leage, Soyi Liu
    El Baou, Celine
    Bradley, Andrew J.
    Meszaros, Gabriella
    de Vlam, Kurt
    RHEUMATOLOGY, 2021, 60
  • [40] Efficacy of Ixekizumab versus Adalimumab in Psoriatic Arthritis (PsA) Patients with and Without Moderate-to-severe Psoriasis: 52-week Results from a Multicentre, Randomised Open-label Study
    Kristensen, Lars Erik
    Okada, Masato
    Tillett, William
    Liu-Leage, Soyi
    El Baou, Celine
    Bradley, Andrew
    Meszaros, Gabriella
    de Vlam, Kurt
    ARTHRITIS & RHEUMATOLOGY, 2020, 72
12345